EPRX
NASDAQ · Biotechnology
Eupraxia Pharmaceuticals Inc
$6.40
-0.15 (-2.29%)
Open$6.55
Previous Close$6.55
Day High$6.74
Day Low$6.15
52W High$12.86
52W Low$6.94
Volume—
Avg Volume59.1K
Market Cap609.50M
P/E Ratio—
EPS$-0.96
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+592.8% upside
Current
$6.40
$6.40
Target
$44.34
$44.34
$25.23
$44.34 avg
$48.95
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 121.08M | 121.80M | 129.11M |
| Net Income | -20,292,332 | -19,070,968 | -17,081,441 |
| Profit Margin | -16.8% | -15.7% | -13.2% |
| EBITDA | -26,386,283 | -29,891,368 | -27,935,877 |
| Free Cash Flow | -23,062,869 | -20,449,670 | -23,278,243 |
| Rev Growth | +21.7% | +19.1% | -8.5% |
| Debt/Equity | 0.16 | 0.18 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |